Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clene Inc
(NQ:
CLNN
)
5.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clene Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
October 10, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
October 09, 2024
Via
Investor Brand Network
Disruptions in Purine Metabolism Cited in Parkinson’s Development
October 02, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
October 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
October 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Researchers Identify New Gene Behind ALS Onset
July 29, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
September 30, 2024
Via
Investor Brand Network
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
September 26, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
September 24, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
September 16, 2024
Via
Investor Brand Network
Exposures
Product Safety
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
September 11, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
September 11, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
September 06, 2024
Via
Investor Brand Network
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 06, 2024
Via
Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
August 30, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
August 28, 2024
Via
Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
August 22, 2024
Via
Investor Brand Network
Exposures
Product Safety
UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis
August 19, 2024
Via
Investor Brand Network
Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease
August 12, 2024
Via
Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions
August 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
August 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
August 07, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA
August 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics
August 06, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
August 05, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast
July 26, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature
July 23, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction
July 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
July 17, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.